In a bold move signaling India’s intent to transform its pharmaceutical landscape, the Union Budget 2026-27 has significantly raised the funding for the Department of Pharmaceuticals […]
Union Budget 2026, unveiled by Finance Minister Nirmala Sitharaman, put a strong spotlight on healthcare, especially with the ambitious Biopharma SHAKTI scheme — a transformative initiative […]
ndia’s regulatory spotlight is shifting. The Drugs Controller General of India (DCGI) has recently launched an aggressive crackdown on small- and medium-sized pharmaceutical manufacturers—particularly those in […]
When the Patents Act, 1970’s Section 3(d) came into sharper focus through the Novartis AG v. Union of India ruling and subsequent cases, it marked more […]
In a world where body weight often dictates health outcomes, the race to develop effective weight-loss medications has morphed into one of the most fiercely contested […]